Apigenin, a flavonoid constituent derived from P. villosa, inhibits hepatocellular carcinoma cell growth by CyclinD1/CDK4 regulation via p38 MAPK-p21 signaling

Li, Yue; Cheng, Xiaoyan; Chen, Chang-Lan; Wu, Huijuan; Zhao, Hong; Liu, Wei; Xiang, Zheng; Wang, Qi

doi:10.1016/j.prp.2019.152701

Cited by 45 publications

(30 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Reduced cell viability and proliferation [359][360][361]. Induced cell cycle arrest at the G1 or G2/M phase [360,362,363]. Inhibited hypoxia-induced resistance via suppression of HIF-1α [362].…”

Section: Apigeninmentioning

confidence: 99%

“…Induced cell cycle arrest at the G1 or G2/M phase [360,362,363]. Inhibited hypoxia-induced resistance via suppression of HIF-1α [362]. Enhanced activity of paclitaxel [362].…”

Section: Apigeninmentioning

confidence: 99%

“…Inhibited hypoxia-induced resistance via suppression of HIF-1α [362]. Enhanced activity of paclitaxel [362]. Apigenin + Sorafenib increased apoptosis and decreased migration and invasion [364].…”

Section: Apigeninmentioning

confidence: 99%

“…Exacerbated the effects of paclitaxel [362]. Inhibited tumor growth via ER-mediated PI3K/Akt/mTOR pathway [365].…”

Section: Apigeninmentioning

confidence: 99%

See 3 more Smart Citations

Anti-Cancer Potential of Cannabinoids, Terpenes, and Flavonoids Present in Cannabis

Tomko

Whynot

Ellis

et al. 2020

Cancers

160

139

View full text Add to dashboard Cite

In recent years, and even more since its legalization in several jurisdictions, cannabis and the endocannabinoid system have received an increasing amount of interest related to their potential exploitation in clinical settings. Cannabinoids have been suggested and shown to be effective in the treatment of various conditions. In cancer, the endocannabinoid system is altered in numerous types of tumours and can relate to cancer prognosis and disease outcome. Additionally, cannabinoids display anticancer effects in several models by suppressing the proliferation, migration and/or invasion of cancer cells, as well as tumour angiogenesis. However, the therapeutic use of cannabinoids is currently limited to the treatment of symptoms and pain associated with chemotherapy, while their potential use as cytotoxic drugs in chemotherapy still requires validation in patients. Along with cannabinoids, cannabis contains several other compounds that have also been shown to exert anti-tumorigenic actions. The potential anti-cancer effects of cannabinoids, terpenes and flavonoids, present in cannabis, are explored in this literature review.

show abstract

Section: Apigeninmentioning

confidence: 99%

“…Induced cell cycle arrest at the G1 or G2/M phase [360,362,363]. Inhibited hypoxia-induced resistance via suppression of HIF-1α [362]. Enhanced activity of paclitaxel [362].…”

Section: Apigeninmentioning

confidence: 99%

Section: Apigeninmentioning

confidence: 99%

“…Exacerbated the effects of paclitaxel [362]. Inhibited tumor growth via ER-mediated PI3K/Akt/mTOR pathway [365].…”

Section: Apigeninmentioning

confidence: 99%

See 2 more Smart Citations

Anti-Cancer Potential of Cannabinoids, Terpenes, and Flavonoids Present in Cannabis

Tomko

Whynot

Ellis

et al. 2020

Cancers

160

139

View full text Add to dashboard Cite

show abstract

“…A previous study revealed that menadione kills tumor cells by influencing their redox cycle (45). In addition, other small molecular compounds that act on the cell cycle are apigenin, luteolin and doxorubicin, while further small molecular compounds that are associated with the p53 pathway are irinotecan and doxorubicin (89)(90)(91)(92)(93). Given the broad spectrum of these small molecular compounds, it is not surprising that these compounds may act as promising therapeutic targets for HBV-associated early stage HCC.…”

Section: Discussionmentioning

confidence: 99%

Identification of diagnostic and prognostic biomarkers, and candidate targeted agents for hepatitis B virus‑associated early stage hepatocellular carcinoma based on RNA‑sequencing data

2020

View full text Add to dashboard Cite

Primary liver cancer is a rapidly progressing neoplasm with high morbidity and mortality rates. The present study aimed to identify potential diagnostic and prognostic biomarkers, and candidate targeted agents for hepatitis B virus (HBV)-associated early stage hepatocellular carcinoma (HCC). The gene expression profiles were extracted from the Gene Expression Omnibus database. Differentially expressed genes (DEGs), hub genes and the enrichment of signaling pathways were filtered out via a high-throughput sequencing method. The association between hub genes and the effects of the abnormal expression of hub genes on the rate of genetic variation, overall survival (OS), relapse-free survival (RFS), progression-free survival (PFS) and disease-free survival (DSS) of patients with HCC, as well as pathological stage and grade, were analyzed using different databases. A total of 1,582 DEGs were identified. Gene Ontology analysis revealed that the DEGs were mainly involved in the 'oxidation-reduction process', 'steroid metabolic process', 'metabolic process' and 'fatty acid beta-oxidation'. Enrichment analysis of Kyoto Encyclopedia of Genes and Genomes pathways revealed that the DEGs were mainly associated with 'metabolic pathways', 'PPAR signaling pathway', 'fatty acid degradation' and the 'cell cycle'. A total of 8 hub genes were extracted. Additionally, the abnormal expression levels of hub genes were closely associated with the OS, RFS, PFS and DSS of patients, the pathological stage and the grade. Furthermore, abnormal expression levels of the 8 hub genes were found in >30% of all samples. Several small molecular compounds that may reverse the altered DEGs were identified based on Connectivity Map analysis, including phenoxybenzamine, GW-8510, resveratrol, 0175029-0000 and daunorubicin. In conclusion, the dysfunction of fat metabolic pathways, the cell cycle, oxidation-reduction processes and viral carcinogenesis may serve critical roles in the occurrence of HBV-associated early stage HCC. The identified 8 hub genes may act as robust biomarkers for diagnosis and prognosis. Some small molecular compounds may be promising targeted agents against HBV-associated early stage HCC.

show abstract

Apigenin as an anticancer agent

Imran

Gondal

Atif

et al. 2020

Phytotherapy Research

175

View full text Add to dashboard Cite

Apigenin is an edible plant‐derived flavonoid that has been reported as an anticancer agent in several experimental and biological studies. It exhibits cell growth arrest and apoptosis in different types of tumors such as breast, lung, liver, skin, blood, colon, prostate, pancreatic, cervical, oral, and stomach, by modulating several signaling pathways. Apigenin induces apoptosis by the activation of extrinsic caspase‐dependent pathway by upregulating the mRNA expressions of caspase‐3, caspase‐8, and TNF‐α. It induces intrinsic apoptosis pathway as evidenced by the induction of cytochrome c, Bax, and caspase‐3, while caspase‐8, TNF‐α, and B‐cell lymphoma 2 levels remained unchanged in human prostate cancer PC‐3 cells. Apigenin treatment leads to significant downregulation of matrix metallopeptidases‐2, −9, Snail, and Slug, suppressing invasion. The expressions of NF‐κB p105/p50, PI3K, Akt, and the phosphorylation of p‐Akt decreases after treatment with apigenin. However, apigenin‐mediated treatment significantly reduces pluripotency marker Oct3/4 protein expression which might be associated with the downregulation of PI3K/Akt/NF‐κB signaling.

show abstract

Apigenin, a flavonoid constituent derived from P. villosa, inhibits hepatocellular carcinoma cell growth by CyclinD1/CDK4 regulation via p38 MAPK-p21 signaling

Cited by 45 publications

References 40 publications

Anti-Cancer Potential of Cannabinoids, Terpenes, and Flavonoids Present in Cannabis

Anti-Cancer Potential of Cannabinoids, Terpenes, and Flavonoids Present in Cannabis

Identification of diagnostic and prognostic biomarkers, and candidate targeted agents for hepatitis B virus‑associated early stage hepatocellular carcinoma based on RNA‑sequencing data

Apigenin as an anticancer agent

Contact Info

Product

Resources

About